Breadcrumb

[A19-01] Nivolumab (melanoma) -Addendum to Commission A18-53

Overview

Overview

Commission: Commission awarded on 2019-01-07 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A18-53  [PDF, 519 kB] (German version) Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-02-21 Addendum to Commission A18-53 (German version) 519 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Health information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Nivolumab (Opdivo) for the treatment of melanoma

Federal Joint Committee (G-BA)

2019-02-21 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close